Idiopathic Membranous Nephropathy Clinical Trial
Official title:
A Prospective Cohort Study of Membranous Nephropathy-associated Serological Antibody in Prediction of the Prognosis of Idiopathic Membranous Nephropathy
Idiopathic membranous nephropathy (IMN) remains a common cause of the nephrotic syndrome in adults and one of the leading known causes of end-stage renal disease. Identification of circulating autoantigens provide potential biomarkers for diagnosis and therapy of idiopathic membranous nephropathy. M-type phospholipase A2 receptor (PLA2R) and Thrombospondin type-I domain-containing 7A (THSD7A) were identified as the target antigen in membranous nephropathy with high specificity and the concentration of serum anti-PLA2R antibody and anti-TSHD7A antibody were helpful for predicting disease activity. In our prospective cohort study, hospitalized patients diagnosed as IMN are prospectively studied. Circulating anti-PLA2R antibody and anti-THSD7A antibodies were recently screened by using enzyme-linked sorbent assay(ELISA). This study aims to analyse the difference of clinicopathological characteristics for different concentrations of serum anti PLA2R antibody and anti TSHD7A antibody, and analyze the association between baseline concentrations of serum antibody and disease activity. This study also explored the prediction effects of serum antibody concentrations with different types of therapeutic regimen in IMN and compare the curative effects of different types of therapeutic regimen in different serum antibody concentrations.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06245707 -
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
| Recruiting |
NCT03864250 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
|
N/A | |
| Completed |
NCT01845688 -
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
|
N/A | |
| Completed |
NCT01180036 -
MEmbranous Nephropathy Trial Of Rituximab
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT01093781 -
Aliskiren in Patients With Idiopathic Membranous Nephropathy
|
N/A | |
| Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
| Completed |
NCT00302523 -
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
| Terminated |
NCT03466801 -
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
|
N/A | |
| Not yet recruiting |
NCT05850845 -
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
|
||
| Not yet recruiting |
NCT05667896 -
Prognostic Model of GC/TAC in the Treatment of MN
|
||
| Not yet recruiting |
NCT05667922 -
Prognostic Model of TAC in the Treatment of MN
|
||
| Not yet recruiting |
NCT05667909 -
Prognostic Model of Rituximab in the Treatment of MN
|
||
| Not yet recruiting |
NCT05667883 -
Prognostic Model of GC/CTX in the Treatment of MN
|
||
| Recruiting |
NCT02173106 -
A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy
|
Phase 2 | |
| Completed |
NCT01161459 -
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
|
N/A | |
| Recruiting |
NCT03549663 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)
|
N/A | |
| Not yet recruiting |
NCT05845762 -
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
|
||
| Completed |
NCT00694863 -
Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy
|
Phase 2 | |
| Recruiting |
NCT03170323 -
Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy
|
Phase 4 |